- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:06 | Elutia Reports Q1 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| Do | Elutia reports Q1 results, expects FDA clearance for NXT-41 | 1 | Investing.com | ||
| Do | Elutia: EPS verfehlt Schätzungen um 0,02 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| Do | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Elutia Inc.: Elutia to Present at the 16th Annual LD Micro Invitational on May 18th | 1 | GlobeNewswire (USA) | ||
| Do | LD Micro: Elutia to Present at the 16th Annual LD Micro Invitational May 18th | 214 | Newsfile | Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Elutia Inc. (NASDAQ: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy... ► Artikel lesen | |
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 25.03. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 13.03. | ELUTIA INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | Elutia Inc.: Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.03. | Elutia outlines launch timeline for NXT-41x in $1.5B breast reconstruction market while strengthening leadership team | 1 | Seeking Alpha | ||
| 11.03. | Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction | 1 | Investing.com | ||
| 11.03. | Earnings Call Transkript: Elutia übertrifft Prognosen für Q4 2025 deutlich - Aktie reagiert verhalten | 4 | Investing.com Deutsch | ||
| 11.03. | Elutia GAAP EPS of $1.48 beats by $1.62, revenue of $3.3M in-line | 2 | Seeking Alpha | ||
| 10.03. | Exploring Elutia's Earnings Expectations | 1 | Benzinga.com | ||
| 04.03. | Elutia regains full Nasdaq listing compliance | 1 | Seeking Alpha | ||
| 04.03. | Elutia erfüllt wieder die Nasdaq-Notierungsanforderungen | 1 | Investing.com Deutsch | ||
| 04.03. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.03. | Elutia names Pete Ligotti chief commercial officer | 2 | Investing.com | ||
| 12.01. | Elutia reports 16% revenue growth, advances breast reconstruction product | 1 | Investing.com | ||
| 12.01. | Elutia sees Q4 net sales of $3.3M | 1 | Seeking Alpha |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,590 | +0,85 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,700 | +3,52 % | Mit guten Konzepten und Entspannung im Nahost-Konflikt voran! MustGrow, K+S, Evotec und Novo Nordisk im Fokus | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Was für eine Nachricht: Einigung zwischen USA und dem Iran - Märkte plus 2 % in nur 1 Minute! So schnell kann es gehen. Für Investoren... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,890 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| CG ONCOLOGY | 69,54 | -6,03 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,775 | 0,00 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| BIONTECH | 78,75 | -0,25 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,140 | 0,00 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| ASSERTIO | 23,315 | -0,02 % | Assertio Holdings, Inc. to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash | All-Cash Tender Offer of $23.50 per share or $166.4 Million
Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price
LAKE FOREST, Ill.--(BUSINESS... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,81 | -0,30 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,495 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| ERASCA | 10,370 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,530 | 0,00 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| SEPTERNA | 28,340 | +14,51 % | Septerna, Inc.: Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results | Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,570 | -0,55 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| CANDEL THERAPEUTICS | 8,900 | 0,00 % | Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026Announced purpose-built... ► Artikel lesen |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,045 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.